A novel blood test analyzing fragments of cell-free DNA showed robust diagnostic performance for colorectal cancer across clinical subgroups, offering a promising noninvasive screening method.

A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

A new cfDNA-based blood test uses AI to detect bladder, prostate, and kidney cancers early, offering a faster, safer, and ...

Natera Inc., a cell-free DNA and precision medicine company, has acquired Foresight Diagnostics, a leader in ultrasensitive ...

An Arizona veteran who learned he has ALS is exploring a new blood test that researchers at UCLA are studying.

An Austin, Texas-based genetics-testing company that specializes in cell-free DNA and precision medicine has acquired Foresight Diagnostics Inc., a Boulder-based cancer-diagnostics company.

The market offers significant opportunities in non-invasive cancer diagnostics using in vitro blood tests, with potential to replace traditional biopsies. Key areas include screening, diagnosis, ...

A man treated for blood cancer has stayed HIV-free for seven years after a stem-cell transplant, even without the CCR5 ...

Cancer usually grows quietly for years before it causes pain, bleeding or weight loss. By the time symptoms appear, disease may already have spread, making treatment harder and survival chances lower ...